港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

維立志博-B

54.600

-3.400-5.86%

成交量：71.19萬

成交額：3,927.10萬

市值：108.65億

市盈率：-27.19

高：58.300

開：57.750

低：53.800

收：58.000

52周最高：83.600

52周最低：51.600

股本：1.99億

香港流通股本：1.53億

量比：1.74

換手率：0.47%

股息：- -

股息率：- -

每股收益(LYR):-2.008

淨資產收益率：--

總資產收益率：--

市淨率：94.64

市盈率(LYR):-27.19

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

一週IPO觀察：維立志博超40倍國配首日近翻倍，歌爾微、天域半導體等遞表；設計軟件獨角獸Figma美股上市在即

孖展申購倍數超3000倍，維立志博首日最高漲127%

览富财经网

年薪1171萬的普華永道背景CFO助力！又一獨角獸IPO敲鐘！

136億！南京獨角獸IPO，開盤大漲120%！

開盤大漲107%：維立志博今日港股上市

維立志博-B(09887)：獨立非執行董事杜季柳獲委任為提名委員會的成員

中信證券保薦維立志博完成今年以來超額認購倍數最高的港股18A IPO

中信证券发布

港股綜述｜半導體板塊逆勢走強，華虹半導體漲超9%；維立志博-B首掛大漲近92%

老虎资讯综合

港股收評：三大指數均跌超1%，科技金融低迷，半導體股午後異動大幅拉昇

一個醫藥IPO大漲100%

今天南京獨角獸IPO敲鐘，大漲100%

市值超135億！八旬創始人今日敲鐘

維立志博登陸港交所，為南京江北新區今年第二家上市企業

港股午評：高位回調！恒指跌1.11%止步5連漲，科技股、金融股低迷

招銀國際作為整體協調人、聯席全球協調人助力維立志博IPO成功發行並在香港聯交所主板掛牌上市

維立志博攜4-1BB靶點全球首成藥產品在港交所正式掛牌上市

「中國TCE第一股」開盤大漲126%！維立志博正式登陸港交所，多元佈局領跑腫瘤免疫治療2.0時代

独角兽早知道

《股市簡訊》中國生物科技公司維立志博香港「首秀」，盤中一度漲127%

異動解讀 | 維立志博-B首日掛牌大漲115.71%，創新藥企IPO獲3494倍超額認購

港股早評：三大指數低開金融股回調有色金屬股、水泥股強勢

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":54.6,"timestamp":1763453299006,"preClose":58,"halted":0,"volume":711932,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盤","change":-3.4,"latestTime":"11-18 16:08:19","open":57.75,"high":58.3,"low":53.8,"amount":39271015,"amplitude":0.077586,"askPrice":54.75,"askSize":400,"bidPrice":54.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1763515800000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":58,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":1.739406,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.739406,"shares":199000000,"dividePrice":0,"high":58.3,"amplitude":0.077586,"preClose":58,"low":53.8,"week52Low":51.6,"pbRate":"94.64","week52High":83.6,"institutionHeld":0,"latestPrice":54.6,"committee":-0.333333,"eps":-2.008042,"divideRate":0,"volume":711932,"delay":0,"ttmEps":-1.858667,"open":57.75,"prevYearClose":35,"prevWeekClose":59,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":59.35,"twentyDayClose":65,"sixtyDayClose":70},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-17","current":-29.375891,"percent":0.923077,"low":-50.052922,"twenty":-43.982813,"median":-41.479633,"eighty":-37.985718,"high":-34.030535,"avg":-41.267877,"sd":3.199788,"marketCap":11535724400},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-17","current":-36.723723,"twenty":-43.982813,"median":-41.479633,"eighty":-37.985718,"marketCap":11535724400}],"updateTime":1763480048748},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554747121","title":"一週IPO觀察：維立志博超40倍國配首日近翻倍，歌爾微、天域半導體等遞表；設計軟件獨角獸Figma美股上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2554747121","media":"FX168","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554747121?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 11:18","pubTimestamp":1753672717,"startTime":"0","endTime":"0","summary":"截止2025年的第30周，港交所无新股上市，1家上市，1家招股，1家聆讯，9家递表。维立志博-B招股结束并于7月25日上市，募资12.90亿港元，市场申购火热，国配超40倍。7月25日，福建乐摩物联科技向港交所递交招股书，拟香港主板挂牌上市。7月22日，维立志博-B开启招股，并预计于2025年7月25日在港交所挂牌上市，摩根士丹利、中信证券为其联席保荐人","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fx168news.com/article/921974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIG","09887","02627"],"gpt_icon":1},{"id":"2554074097","title":"孖展申購倍數超3000倍，維立志博首日最高漲127%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554074097","media":"览富财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554074097?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 10:18","pubTimestamp":1753669091,"startTime":"0","endTime":"0","summary":"7月25日，维立志博登陆港交所，股价一度涨127%，收盘涨91.7%，每股报67.1港元，总市值为129.7亿港元。实际上，维立志博在申购期内的火爆程度，已为其上市首日的股价飙升埋下了伏笔。数据显示，维立志博的融资申购倍数超3000倍，融资申购额达到3300亿港元，成为7月以来港股IPO最热新股。维立志博此次IPO全球发售3686.25万股H股，最终每股发售价为35港元，募资总额为12.9亿港元，所得款净额约11.79亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072810181494be5b66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"b96f9e7d8090c255d89984c6a78fb415","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072810181494be5b66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554671787","title":"年薪1171萬的普華永道背景CFO助力！又一獨角獸IPO敲鐘！","url":"https://stock-news.laohu8.com/highlight/detail?id=2554671787","media":"CFO职业圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554671787?lang=zh_tw&edition=fundamental","pubTime":"2025-07-27 10:12","pubTimestamp":1753582365,"startTime":"0","endTime":"0","summary":"维立志博此次IPO的核数师及申报会计师为安永会计师事务所。于2013年9月至2019年3月，左先生于高盛集团有限公司担任执行董事。于2021年8月至2023年11月，左先生于臻和科技集团有限公司担任董事兼首席财务官。董事任期3年，可重选连任。于2023年、2024年及截至2024年及2025年3月31日止三个月，年╱期内全面亏损总额分别为人民币36.23亿元、人民币30.11亿元、人民币8.66亿元及人民币7.51亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250727115731a4656cbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250727115731a4656cbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554715440","title":"136億！南京獨角獸IPO，開盤大漲120%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2554715440","media":"创客公社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554715440?lang=zh_tw&edition=fundamental","pubTime":"2025-07-26 15:31","pubTimestamp":1753515067,"startTime":"0","endTime":"0","summary":"7月25日上午，南京维立志博生物科技股份有限公司在香港交易所主板鸣锣上市，发行价为35港元/股，一度上涨超120% 。截至目前，市值达到136亿港元。据悉，这是南京今年第3家上市企业，至此，南京在香港交易所上市的企业数量达32家。园区已上市药品总数达到405件，其中1类新药达6件，医疗器械产品1261个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726153517a464700e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726153517a464700e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554071578","title":"開盤大漲107%：維立志博今日港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554071578","media":"谈思生物","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554071578?lang=zh_tw&edition=fundamental","pubTime":"2025-07-26 15:01","pubTimestamp":1753513263,"startTime":"0","endTime":"0","summary":"2025.07.26本文字数：461，阅读时长大约1.16分钟导读：7月25日，维立志博港交所首秀飙涨一倍，市值冲140亿港元；PD-L1/4-1BB双抗LBL-024手握“突破疗法”，肺外神经内分泌瘤有望率先撞线，三抗ADC借NewCo出海。2025年7月25日，维立志博正式登陆港交所主板，挂牌首日高开107%，总市值一举冲破140亿港元大关。维立志博创立于2012年，其首发产品LBL-024属于PD-L1×4-1BB双特异性抗体。维立志博携手百凯医药共同推进多款抗体偶联新药项目，其CD3/CD19/BCMA三特异性抗体则借助NewCo模式扬帆出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726150353a4646952&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726150353a4646952&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2554793748","title":"維立志博-B(09887)：獨立非執行董事杜季柳獲委任為提名委員會的成員","url":"https://stock-news.laohu8.com/highlight/detail?id=2554793748","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554793748?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 22:40","pubTimestamp":1753454430,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，(i)独立非执行董事杜以龙先生不再为公司提名委员会的成员;及(ii)独立非执行董事杜季柳已获委任为提名委员会的成员，自上市日期起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887"],"gpt_icon":0},{"id":"2554907217","title":"中信證券保薦維立志博完成今年以來超額認購倍數最高的港股18A IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554907217","media":"中信证券发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554907217?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 19:55","pubTimestamp":1753444500,"startTime":"0","endTime":"0","summary":"2025年7月25日，南京维立志博生物科技股份有限公司成功在香港联交所主板上市，基础发行规模1.43亿美元，发售量调整权和超额配售权均悉数行使后，最高发行规模1.89亿美元，中信证券担任联席保荐人、联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。本项目也是今年以来融资规模第二大的港股18A IPO项目，至此，中信证券以保荐人身份参与了2022年以来港股市场最大的三单18A IPO项目，项目执行和发行能力获得市场的高度认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726090303a6c26891&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726090303a6c26891&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06030","09887","BK1516","BK1521","LU1720050803.USD","BK1564","BK1147","LU1794554557.SGD","HSCEI","HSTECH"],"gpt_icon":1},{"id":"1135975303","title":"港股綜述｜半導體板塊逆勢走強，華虹半導體漲超9%；維立志博-B首掛大漲近92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135975303","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135975303?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 16:30","pubTimestamp":1753432200,"startTime":"0","endTime":"0","summary":"半导体板块逆势走强，$华虹半导体$涨超9%，$中芯国际$、$上海复旦$涨近5%；机构看好AI和国产化打开成长空间。新股$维立志博-B$首日大幅收涨91.7%；此前公开发售阶段维立志博-B获3494.78倍认购，一手中签率0.27%。海南自贸区板块回调，半导体板块逆势拉升7月25日，A股主要指数集体下跌，沪指跌0.33%报3593点，深证成指跌0.22%，创业板指跌0.23%。全市场超2700股下跌。","market":"sh","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01347","HSI","09887","HSTECH"],"gpt_icon":0},{"id":"2554375278","title":"港股收評：三大指數均跌超1%，科技金融低迷，半導體股午後異動大幅拉昇","url":"https://stock-news.laohu8.com/highlight/detail?id=2554375278","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554375278?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 16:20","pubTimestamp":1753431649,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3bdd4ce769eda6858f982fbc209d3ce7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PAImain","688981","METmain","03690","600030","02833","MPNGY","03908","600801","AAGIY","02318","HSImain","MHImain","TTTN","601318","01024","KSTmain","HSTECH","00981","601766","JD","07226","HSCEI","601939","513600","06030","06655","03086","HHImain","LU","PNGAY","BABA","YANG","01800","ALBmain","03145","01810","601288","MCHmain","MIUmain","00939","HSI","01766","01288","01299","09887","601995","82318","01347","09618"],"gpt_icon":0},{"id":"2554796486","title":"一個醫藥IPO大漲100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796486","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796486?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 15:33","pubTimestamp":1753428780,"startTime":"0","endTime":"0","summary":"截至目前，市值达到136亿港元。回望过去半年，港股生物医药IPO钟声不断。而报告期内唯一一笔近900万元的收入，来自百济神州。兜兜转转13年，康小强与赖寿鹏终于迎来人生第一个IPO。其核心在研产品HY1001，有望成为国内首个上市的重组人白蛋白药品。随后上周，北芯生命IPO顺利通过审核。科创板之外，港股医药类IPO十分火热。恒瑞医药以98.9亿港元募资额创下近五年最大医药IPO，首日股价涨超25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154107a462cf13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154107a462cf13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","09939","BK1161","09887"],"gpt_icon":1},{"id":"2554431750","title":"今天南京獨角獸IPO敲鐘，大漲100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554431750","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554431750?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 14:50","pubTimestamp":1753426200,"startTime":"0","endTime":"0","summary":"截至目前，市值达到136亿港元。今天，他们联手IPO敲钟康小强，出生于1961年，于1985年获得湖北医学院学士学位后，进入同济医科大学、北得克萨斯大学深造，并取得硕博学位。早在2015年，维立志博完成天使轮融资，由南京凯元、上海庄钟合计增资33.33万元，作价1000万元。其核心在研产品HY1001，有望成为国内首个上市的重组人白蛋白药品。随后上周，北芯生命IPO顺利通过审核。恒瑞医药以98.9亿港元募资额创下近五年最大医药IPO，首日股价涨超25%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-07-25/doc-infhsmty5040283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4202","NCI","159982","09887"],"gpt_icon":1},{"id":"2554796086","title":"市值超135億！八旬創始人今日敲鐘","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796086","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796086?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 14:08","pubTimestamp":1753423716,"startTime":"0","endTime":"0","summary":"据悉，维立志博全球发售3686.25万股H股股份，香港公开发售占43.48%，国际发售占56.52%。本次发售中，香港公开发售获大幅超额认购，认购倍数高达3494.78倍，国际发售也获得40.78倍认购。彼时，创始人之一的赖寿鹏已经年过六旬。招股书显示，公司目前拥有14款在研药物，其中6款已进入临床试验阶段，包括核心产品LBL-024和主要产品LBL-034、LBL-033、LBL-007等。从财务数据来看2023年、2024年、2025年一季度分别亏损3.62亿元、3.01亿元及7536.7万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725140846971da715&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725140846971da715&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554796438","title":"維立志博登陸港交所，為南京江北新區今年第二家上市企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796438","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796438?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 12:26","pubTimestamp":1753417560,"startTime":"0","endTime":"0","summary":"据介绍，LBL-024的首发适应症为肺外神经内分泌癌，针对这一恶性肿瘤，目前临床缺少有效治疗手段。值得一提的是，就在一个月前，南京江北新区企业药捷安康也在港交所鸣锣上市。药企争相上市的背后，是南京江北新区生命健康产业发展如火如荼。截至目前，园区上市药品总数达到405件，其中1类新药达6件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725122808971d7c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725122808971d7c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554066758","title":"港股午評：高位回調！恒指跌1.11%止步5連漲，科技股、金融股低迷","url":"https://stock-news.laohu8.com/highlight/detail?id=2554066758","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554066758?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 12:00","pubTimestamp":1753416044,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"af64bc9a59ab38ec2fb4392457afd99f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09887","89618","03086","02833","LU2226246903.HKD","TCEHY","HMTD.SI","YANG","BABA","HSI","01810","07226","08496","81810","LU0797268264.HKD","MIUmain","81024","TSYW.SI","BK4581","TSLA","METmain","HSImain","XIACY","BIDU","00700","HHImain","HSTECH","BK4551","MHImain","KSTmain","HSCEI","HXXD.SI","LU0048597586.USD","JD","MPNGY","TTTN","LU1956131251.USD","TSLL","ALBmain","TCHmain","161032","MCHmain","09618","01024","LU1993786604.SGD","03690","09988","513600","HTCD.SI"],"gpt_icon":0},{"id":"2554964337","title":"招銀國際作為整體協調人、聯席全球協調人助力維立志博IPO成功發行並在香港聯交所主板掛牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554964337","media":"招银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554964337?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 10:08","pubTimestamp":1753409286,"startTime":"0","endTime":"0","summary":"交易概述2025年7月25日，南京维立志博生物科技股份有限公司成功在香港联合交易所主板挂牌上市。招银国际担任维立志博在香港IPO的整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。作为招商银行境外综合金融服务业务旗舰平台，招银国际融资实施“立足香港，深植内地，面向全球”的发展战略。招银国际融资已逐步成为香港资本市场最为活跃且增长力强劲的金融机构之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113131a6c0c9e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"2be6df3677c49ea3193469949bfbb28d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113131a6c0c9e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554799343","title":"維立志博攜4-1BB靶點全球首成藥產品在港交所正式掛牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554799343","media":"药智网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554799343?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 09:56","pubTimestamp":1753408568,"startTime":"0","endTime":"0","summary":"7月24日，维立志博在香港联合交易所主板正式挂牌上市，股票代码为9887.HK，预计募集资金总额可达1.89亿美元（含绿鞋），其中所得款项净额约46.0%将用于核心产品LBL-024的持续临床开发。该药在临床研究中展现强大的抗肿瘤活性，有望成为全球首个上市的4-1BB靶点药物。维立志博预计将在2026年提交BLA，并于2027年获得附条件批准，拿下全球首个EP-NEC治疗药物徽章。而LBL-024是进展最快的4-1BB抗体，有望成为全球首个，并在4-1BB抗体市场占据重要份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100148a6c09bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"2be6df3677c49ea3193469949bfbb28d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100148a6c09bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554530737","title":"「中國TCE第一股」開盤大漲126%！維立志博正式登陸港交所，多元佈局領跑腫瘤免疫治療2.0時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2554530737","media":"独角兽早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554530737?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 09:50","pubTimestamp":1753408200,"startTime":"0","endTime":"0","summary":"维立志博是一家临床阶段生物科技公司，专注于肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发及商业化。自2012年创立以来，维立志博始终专注于解决肿瘤、自身免疫性疾病等重大疾病领域未满足的临床需求。在IO 2.0领域，以PD-1/4-1BB双特异性抗体LBL-024为代表，通过多靶点调控激活抗肿瘤免疫。在TCE平台，维立志博则布局了LBL-034、LBL-033等双抗及LBL-051三抗，直接引导T细胞杀伤肿瘤。与此同时，LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2be6df3677c49ea3193469949bfbb28d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2025-07-25/doc-infhrzcx1981666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","HEXmain"],"gpt_icon":1},{"id":"2554310732","title":"《股市簡訊》中國生物科技公司維立志博香港「首秀」，盤中一度漲127%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554310732","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554310732?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 09:43","pubTimestamp":1753407835,"startTime":"0","endTime":"0","summary":"《股市简讯》中国生物科技公司维立志博香港“首秀”，盘中一度涨127%* 南京维立志博生物科技股份有限公司9887.HK周五香港首日挂牌开高107%后，盘中一度扩大涨幅至127%，触及79.6港元。* 这家专注于肿瘤及自身免疫性疾病疗法的公司此前以招股价区间顶端的每股35港元定价，香港首次公开发售集资12.9亿港元，公开发售及国际配售分别获近3,494倍及40倍超额认购。* 香港股市恒生指数.HSI盘中跌0.5%，恒生生物科技指数.HSHKBIO涨0.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2be6df3677c49ea3193469949bfbb28d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nL4S3TM03Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1128548340","title":"異動解讀 | 維立志博-B首日掛牌大漲115.71%，創新藥企IPO獲3494倍超額認購","url":"https://stock-news.laohu8.com/highlight/detail?id=1128548340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128548340?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 09:32","pubTimestamp":1753407158,"startTime":"0","endTime":"0","summary":"7月25日，创新药企维立志博-B在港交所主板挂牌上市，盘中大涨115.71%，引发市场广泛关注。该公司此前公开发售部分获3494.78倍超额认购，最终以每股35港元的上限价格定价，募集资金净额约11.79亿港元。维立志博是一家专注于肿瘤免疫疗法的临床阶段生物科技公司，致力于开发突破性癌症疗法。尽管维立志博上市首日表现亮眼，但作为尚未盈利的生物科技公司，其未来发展仍面临研发风险、激烈的市场竞争以及商业化挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2be6df3677c49ea3193469949bfbb28d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"gpt_icon":0},{"id":"2554734627","title":"港股早評：三大指數低開 金融股回調 有色金屬股、水泥股強勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734627","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554734627?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 09:28","pubTimestamp":1753406899,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ALBmain","81024","01024","02233","00914","600801","01772","TCHmain","09618","165316","03330","YANG","BABA","09696","161715","HSI","002466","03086","07226","000819.SH","TTTN","161032","HHImain","002460","89618","MCHmain","BIDU","09887","HXXD.SI","159871","MIUmain","HSTECH","81810","06655","000979.SH","HTCD.SI","TCEHY","MHImain","KSTmain","HSCEI","HSImain","01299","81299","02833","600585","00700","JD","01810"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":154,"code":"91000000","status":"200"}]}}